Rapid response to the combination of lenvatinib and pembrolizumab in patients with advanced carcinomas (Lung adenocarcinoma and malignant pleural mesothelioma)

Walid Shalata, Muhammed Iraqi, Baisali Bhattacharya, Vered Fuchs, Laila C. Roisman, Ahron Yehonatan Cohen, Ismaell Massalha, Alexander Yakobson, Manu Prasad, Moshe Elkabets, Angel Porgador, Nir Peled

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

The new era of cancer treatments has made immune checkpoint inhibitors (ICIs) and emerging multikinase inhibitors (TKIs) the standards of care, thus drastically improving patient prognoses. Pembrolizumab is an anti-programmed cell death-1 antibody drug, and lenvatinib is a TKI with preferential antiangiogenic activity. We present, to our knowledge, the first reported series of cases consisting of patients with metastatic non–small cell lung cancer and malignant pleural mesothelioma who were treated with several types of chemotherapy combinations and ICIs fol-lowed by disease progression. They were subsequently treated with combined immunotherapy and TKI treatment, resulting in a near complete response within a very short time. Clinical responses were supported by in vitro testing of each patient’s lymphocytic response to pembrolizumab after pre-exposure of target cancer cells to lenvatinib.

Original languageEnglish
Article number3630
JournalCancers
Volume13
Issue number14
DOIs
StatePublished - 2 Jul 2021

Keywords

  • Immune checkpoint inhibitor
  • Lenvatinib
  • Lung adenocarcinoma
  • Malignant pleural mesothelioma
  • Multikinase inhibitor
  • NSCLC
  • Pembrolizumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Rapid response to the combination of lenvatinib and pembrolizumab in patients with advanced carcinomas (Lung adenocarcinoma and malignant pleural mesothelioma)'. Together they form a unique fingerprint.

Cite this